Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombin-activatable fibrinolysis inhibitor.

Pauline F Marx1

  • 1Dept. Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. P.F.Marx@amc.uva.nl

Current Medicinal Chemistry
|September 24, 2004
PubMed
Summary

Thrombin-activatable fibrinolysis inhibitor (TAFI) links blood clotting and clot breakdown. Activated TAFI protects fibrin clots by inhibiting plasmin formation, aiding wound healing and potentially inflammation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain Expression of CPB2 and Effects of Cpb2 Deficiency in Mouse Models of Behavior.

Thrombosis and haemostasis·2023
Same author

Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B.

Thrombosis and haemostasis·2011
Same author

The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2010
Same author

The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing.

Thrombosis research·2010
Same author

Activation of TAFI on the surface of Streptococcus pyogenes evokes inflammatory reactions by modulating the kallikrein/kinin system.

Journal of innate immunity·2010
Same author

The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor.

Thrombosis and haemostasis·2009

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • The coagulation system prevents blood loss via enzymatic reactions, generating thrombin.
  • Thrombin converts fibrinogen to fibrin, forming a clot removed by the fibrinolytic system.
  • Thrombin-activatable fibrinolysis inhibitor (TAFI) bridges coagulation and fibrinolysis.

Purpose of the Study:

  • To review recent advancements in Thrombin-activatable fibrinolysis inhibitor (TAFI) research.
  • To elucidate the role of TAFI in linking blood coagulation and fibrinolysis.
  • To discuss TAFI's function in regulating fibrin clot stability and its potential roles in inflammation and tissue repair.

Main Methods:

  • Literature review of recent TAFI research.
  • Analysis of TAFI's mechanism of action in fibrinolysis.
  • Discussion of TAFI's interactions within the coagulation and fibrinolytic pathways.

Main Results:

  • TAFI circulates as an inactive proenzyme, activated during clotting to TAFIa.
  • TAFIa inhibits fibrinolysis by cleaving lysine residues from degraded fibrin.
  • This action reduces plasmin formation, protecting the fibrin clot from degradation.

Conclusions:

  • TAFI plays a critical role in regulating fibrinolysis and maintaining clot integrity.
  • TAFIa's inhibition of plasmin formation contributes to clot stability.
  • TAFI may also influence inflammatory processes and tissue repair mechanisms.

Related Experiment Videos